A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

NCT03490786 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Feeding and Eating Disorders

Interventions

DRUG: GT-001

Sponsor

Gila Therapeutics, Inc.